Compare EVH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | SGHT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 282.9M |
| IPO Year | 2015 | 2021 |
| Metric | EVH | SGHT |
|---|---|---|
| Price | $2.98 | $3.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | $7.93 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 3.1M | 333.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,957,000.00 | $77,363,000.00 |
| Revenue This Year | $33.03 | $13.54 |
| Revenue Next Year | $16.03 | $14.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $2.03 |
| 52 Week High | $11.92 | $9.24 |
| Indicator | EVH | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 30.62 |
| Support Level | $2.53 | $3.26 |
| Resistance Level | $4.20 | $4.33 |
| Average True Range (ATR) | 0.26 | 0.35 |
| MACD | 0.06 | -0.11 |
| Stochastic Oscillator | 42.68 | 18.84 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.